X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elagolix-sodium-estradiol-norethindrone-acetate-capsules-71055.pdf
https://endpts.com/abbvie-puts-up-fight-against-orilissa-generics-from-sandoz-teva-and-others/
https://endpts.com/under-hub-and-spoke-biotech-serial-founders-launch-new-startup-hoping-to-make-gene-therapies-for-the-eye/
https://news.bloomberglaw.com/health-law-and-business/abbvie-sues-nine-to-block-copies-of-orilissa-endometriosis-drug?context=search&index=13
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-orilissa-elagolix-93966.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-2-2021-1622637119.pdf
https://endpts.com/myovant-shows-disappointing-prostate-cancer-data-on-the-way-to-the-fda-stock-sinks/
https://www.fda.gov/news-events/press-announcements/fda-approves-new-option-treat-heavy-menstrual-bleeding-associated-fibroids-women
https://www.fiercepharma.com/pharma/abbvie-scores-game-changer-nod-for-oriahnn-uterine-fibroids
https://endpts.com/abbvie-wins-an-approval-in-uterine-fibroid-associated-heavy-bleeding-are-rivals-myovant-and-obseva-far-behind/
https://www.fool.com/investing/2020/04/26/myovant-squares-off-with-abbvie-on-endometriosis-t.aspx
https://endometriosisnews.com/2019/08/13/abbvie-files-fda-approval-elagolix-treat-uterine-fibroids-associated-heavy-menstrual-bleeding/
https://www.fiercebiotech.com/biotech/myovant-hits-goal-uterine-fibroid-phase-3-teeing-up-abbvie-showdown
https://endpts.com/jj-beats-novartis-blockbuster-rival-in-a-head-to-head-showdown-over-the-psoriasis-market/
https://www.fiercepharma.com/pharma/abbvie-s-orilissa-makes-its-uterine-fibroids-case-double-phase-3-win
http://www.pmlive.com/pharma_news/abbvie_preps_uterine_fibroid_filing_after_phase_3_win_1260412
https://www.fiercepharma.com/pharma/abbvie-so-far-paid-just-4-5-taxes-versus-same-period-last-year
https://endpts.com/fda-turns-thumbs-down-on-allergans-optimistic-case-for-uterine-fibroid-drug-sends-researchers-back-to-the-drawing-board-on-safety/
https://www.fiercepharma.com/pharma/abbvie-s-blockbuster-potential-orilissa-still-expensive-for-healthcare-budget-icer-report
https://endpts.com/would-abbvies-top-execs-really-pull-the-trigger-on-a-30b-ma-deal-why-yes-actually/
https://www.reuters.com/article/us-abbvie-orilissa/abbvie-prices-new-endometriosis-drug-at-10000-a-year-idUSKBN1KE2O3
https://www.biospace.com/article/icer-report-suggest-abbvie-s-elagolix-could-strain-healthcare-budgets/
http://www.pharmatimes.com/news/us_delay_for_abbvieneurocrines_uterine_pain_drug_1231499
https://in.reuters.com/article/uk-abbvie-fda/fda-needs-more-time-to-review-abbvie-neurocrines-uterine-pain-drug-idINKBN1HH1X0
http://www.pharmatimes.com/news/abbvie,_neurocrines_fibroid_drug_hits_phiii_targets_1227291
https://endpts.com/abbvie-sweeps-back-to-back-phiiis-for-uterine-fibroid-patients-adding-to-elagolixs-blockbuster-rep/
https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-second-phase-3-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids-300612741.html
Market Place
Share 
